Ironwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.34), may not compare to the analyst estimate of ($0.22). Revenue for the quarter came in at $27.7 million versus the consensus estimate of $36.53 million.

2015 Financial Guidance.

Ironwood continues to expect its 2015 total operating expenses to be in the range of $220 million to $250 million, which includes $105 million to $120 million in R&D expenses and $115 million to $130 million in SG&A expenses.
Ironwood continues to expect combined Allergan and Ironwood total 2015 marketing and sales expenses for LINZESS to be in the range of $230 million to $260 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.